#Japan #Tokyo #CMC Research #Protein Degraders #Targeted Protein Degradation

Overview of the New Book

On June 11, 2025, CMC Research, a leading firm in advanced materials science and chemical technologies based in Chiyoda, Tokyo, is set to publish a significant new book titled "Development and Evaluation of Protein Degraders: Technologies and Methods". This book aims to provide an extensive overview of the foundational technologies and evaluation methods essential for the practical application of protein degradation pharmaceuticals.

The book is edited by Mikihiko Naito and Takao Inoue, who are well-respected figures in the field. The retail price for the book is set at ¥100,000 (including tax: ¥110,000), while a special package that includes the book and a CD is available for ¥120,000 (including tax: ¥132,000). Interested readers can start placing their orders immediately, and further details can be accessed through their website.

Book Highlights

• - This comprehensive resource covers the emerging field of protein degradation pharmaceuticals, emphasizing practical technologies and evaluation techniques that are crucial for real-world application.
• - It thoroughly discusses Targeted Protein Degradation (TPD) technologies, outlining both the foundational aspects and the current state of clinical development in this innovative area.
• - The book is crafted not only for researchers across academic and corporate sectors but also for investors looking to tap into the potential of protein degradation therapies.

With recent breakthroughs in PROTAC (Proteolysis Targeting Chimeras) and Molecular Glue technologies, protein degradation pharmaceuticals have garnered significant attention in the pharmaceutical industry. PROTACs bridge target proteins with ubiquitin ligases through engineered linkers, facilitating the rational development of drugs that can degrade specific target proteins by swapping the binding elements. Conversely, Molecular Glue compounds have emerged from traditional phenotypic screening methods, revealing their action mechanism related to target protein degradation, leading to a surge in this method's development.

The pharmacological action of these drugs hinges on selectively degrading target proteins, significantly differing from conventional pharmaceuticals that generally inhibit the functionality of those targets. This unique mechanism allows for the effective breakdown of previously "undruggable" proteins, such as transcription factors lacking enzymatic activity, paving the way for revolutionary advancements in drug discovery.

The contents of the book delve deeply into the foundational aspects of TPD technology, detailing developments and pivotal techniques that are likely to prove beneficial for researchers and enterprises invested in this domain. The authors, comprising a panel of esteemed researchers from both academia and the pharmaceutical industry, provide a well-rounded perspective on the subject matter.

Target Audience

This book is essential for researchers, pharmaceutical professionals, and investors interested in the innovations within the realm of protein degradation pharmaceuticals. With insights into cutting-edge techniques and clinical insights, it acts as a comprehensive guide for anyone engaged in this burgeoning field.

Authors

The contributing authors include prominent researchers and professionals from various institutions, such as:

• - Mikihiko Naito, University of Tokyo
• - Takao Inoue, National Institute of Health Sciences
• - Shin’ichi Oka, National Institute of Health Sciences
• - Satoshi Yamamoto, National Institute of Health Sciences
• - Takuya Ito, Daiichi Sankyo
• - And many more leading figures in this scientific discipline.

Book Structure

The book is meticulously segmented into various parts detailing different aspects of protein degradation pharmaceuticals, including explanations of specific types, clinical development trends, molecular mechanisms, and even future perspectives of drug designs tailored for this innovative treatment approach.

Conclusion

This upcoming publication signifies a crucial contribution to the understanding and development of protein degradation pharmaceuticals. It encapsulates a wealth of knowledge on both foundational technologies as well as the latest advancements, reinforcing the importance of continued research and development in this promising field.

For more information and ordering details, visit CMC Research.